Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for cytarabine (compound)


PubChem
Name: Cytarabine
PubChem Compound ID: 10586353
Description: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Molecular formula: C9H13N3O5
Molecular weight: 244.21 g/mol
DrugBank
Identification
Name: Cytarabine
Name (isomeric): DB00987
Drug Type: small molecule
Description: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Synonyms:
beta-Arabinosylcytosine; Cytosine arabinofuranoside; AraC; Beta-cytosine arabinoside; Cytarabina; Aracytidine; Aracytin; Arabinofuranosylcytosine; Cytosine beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside.
show more »
Brand: Cytarbel, Erpalfa, Iretin, Depocyt (liposomal), Udicil, Alexan, Cytosar-U, Spongocytidine, AR3, Depocyt, Arabitin, Arafcyt, Tarabine, Cytosar
Category: Antimetabolites, Antimetabolites, Antineoplastic, Antineoplastic Agents, Immunosuppressive Agents, Antiviral Agents
CAS number: 147-94-4
Pharmacology
Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Pharmacology:
Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell...
show more »
Mechanism of Action:
Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. A...
show more »
Absorption: Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.
Protein binding: 13%
Biotransformation: Hepatic.
Route of elimination: The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U.
Half Life: 10 minutes
Toxicity: Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DigoxinThe antineoplasic agent decreases the effect of digoxin

Targets


Enzymes


Transporters